

Notice of preliminary results

London, February 8, 2021 – Hikma Pharmaceuticals PLC (Hikma), will announce its preliminary financial results for the year ended 31 December 2020 on Thursday 25 February 2021.

A recording of the presentation will be available on the Company's website at www.hikma.com from 8:00am GMT. Hikma will also hold a live Q&A conference call for analysts at 10:00am GMT, and a recording will be made available on the Company's website later that day.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal
EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050

Teneo

Charles Armitstead
Camilla Cunningham

+44 (0)7703 330 269
+ 44 (0) 7464 982426

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com